More Articles

Questions over DANBIO relevance for non-medical switching Biosimilars/Research | Posted 22/02/2019

Italian rheumatologists Fabrizio Cantini and Maurizio Benucci commented on the paper from Glintborg and co-authors ‘To switch or not to switch’, which reported the results of biosimilar etanercept...

Spanish pharmacists publish biosimilar position statement Reports | Posted 22/02/2019

The Spanish Society of Hospital Pharmacy (Sociedad Española de Farmacia Hospitalaria, SEFH) has published a position statement on the use of biosimilars [1]. The statement expresses the position of...

EC approval for pegfilgrastim biosimilar Fulphila Biosimilars/News | Posted 22/02/2019

In January 2019, the pegfilgrastim biosimilar, Fulphila, received European Commission (EC) approval.

UK pharmacists gain powers to address drug shortages Policies & Legislation | Posted 22/02/2019

Pharmacists in the UK are gaining news powers to be able to dispense alternatives when there are drug shortages.

Biosimilar teriparatide approved for the treatment of osteoporosis Biosimilars/Research | Posted 22/02/2019

Osteoporosis is a modern day epidemic longevity has brought about and represents an enormous socioeconomic burden. Being largely asymptomatic the silent thief can get away with insidiously stealing...

FDA issues new guidance for accelerated pathway for generics Guidelines | Posted 22/02/2019

The US Food and Drug Administration (FDA) announced on 15 February 2019 that it had issued new guidance for its novel accelerated pathway for generics – the Competitive Generic Therapies (CGT) path...

Sandoz makes biological deal in China Pharma News | Posted 22/02/2019

Sandoz has made a deal for copy biological in China in December 2018, and received approval of an extra indication for its biosimilar etanercept in January 2019.

Three FDA approvals for Glenmark as it enters US branded dermatology market Biosimilars/News | Posted 22/02/2019

Glenmark Pharmaceuticals Inc has been granted approval by the US Food and Drug Administration (FDA) for its generic versions of Zytiga, DermOtic oil and Qudexy XR, and has announced its entry into...